Beactica Therapeutics AB
Uppsala
About Beactica Therapeutics AB
Beactica Therapeutics AB is a precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics to treat genetically defined cancers with significant unmet clinical need. Beactica’s approach is centered around targeting disease proteins with synthetic lethality vulnerabilities by applying its molecular interaction-based drug discovery engine to generate novel small molecule across synergistic modalities, including allosteric modulators and targeted protein degraders (PROTACs). Beactica deliver value to patients and shareholders by advancing its programmes into early clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.2M
- Last round: Grant (Feb 2026)
- Website: beactica.com
- Phone: 46 18 56 08 80
Industries & Categories
Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/beactica-therapeutics-ab-123598 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.